MAP2K7 and melanoma: Recently, a phase III clinical trial was proposed aiming to evaluate the safety and efficacy of a combined BRAF+MEK inhibitor (encorafenib+binimetinib) in resected stage II BRAFV600-mutant melanoma patients [41].